Anti Cd 20 Ocrevus denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Ocrevus as "Not FDA-Approved" — and Why This Denial Is Challengeable

Ocrelizumab (Ocrevus) is an FDA-approved medication for both relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. A "not FDA-approved" denial for this drug is almost always the result of one of three administrative errors: (1) the prior-authorization request or claim listed a diagnosis code that does not match the FDA-approved indication; (2) UHC's system applied the wrong drug policy; or (3) the denial was generated automatically based on a formulary or coding mismatch without clinical review.

Because FDA approval is a matter of public record — verifiable on FDA.gov — this type of denial has a strong factual basis for reversal and should be challenged promptly.

## Your Federal Appeal Rights

• Internal appeal: You are entitled to a full-and-fair internal review under ERISA §503 (employer plans) or applicable state law. File within the deadline on the denial notice — typically 180 days.
• External review: Under ACA §2719, adverse benefit determinations — including those based on coverage status — are subject to independent external review. The window is approximately four months from the date of final internal adverse decision. Expedited review (72-hour decision) is available for clinically urgent cases.
• Immediate administrative correction: Before filing a formal appeal, it may be faster to call UHC Provider Services and ask them to review the claim/PA against the FDA-approved package insert. An administrative correction can sometimes resolve this without going through the full appeal process.

## Concrete Steps and Timeline

1. Request the denial letter in full. It must specify the exact policy basis for the "not FDA-approved" determination. 2. Check the diagnosis code submitted. Confirm that the ICD-10 code on the prior-authorization and claim corresponds precisely to the MS subtype covered under the FDA-approved indication for ocrelizumab. A wrong or incomplete code is the most common trigger. 3. Attempt administrative correction first: Have your neurologist's office call UHC and submit a corrected PA request with the precise ICD-10 code and a reference to the FDA approval. Request a real-time review. 4. If administrative correction fails, file the internal appeal with the documentation below. 5. If denied internally, escalate to external review without delay.

## Documentation to Gather

• FDA approval reference: Cite the FDA approval for Ocrevus and the approved indication language. This is publicly available on the FDA Drug Database (FDA.gov). Your neurologist's office can attach the FDA label.
• Diagnosis confirmation matching the approved indication: Neurologist notes, MRI reports, and the specific ICD-10 code(s) establishing the MS subtype that matches the FDA-approved use.
• Correct billing and PA codes: Confirmation from the neurologist's office that the HCPCS/J-code for ocrelizumab, the diagnosis code, and the place-of-service code are all correctly submitted.
• Prescriber attestation letter: A letter from your neurologist stating that ocrelizumab is being prescribed for an FDA-approved indication, identifying that indication, and confirming the diagnosis.
• Medical-necessity context: Even in an administrative appeal, include chart notes documenting clinical severity and the treatment rationale, so the appeal is fully supported if UHC does a clinical review.

## Criteria-Mapping Structure

Obtain UHC's coverage policy for ocrelizumab. For each criterion related to approval status:

| Policy Requirement | Your Evidence | |---|---| | Drug has FDA approval for submitted indication | FDA label, indication text; neurologist letter | | Submitted diagnosis code matches approved indication | ICD-10 code on claim; diagnostic chart note | | Prescriber attestation of on-label use | Neurologist letter dated [date] |

A "not FDA-approved" denial for an approved drug, if not resolved administratively, should go directly to external review after internal denial — IROs assess these appeals against objective FDA records, not UHC's internal systems.